JMT601 / CSPC Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JMT601 / CSPC Pharma
NCT04853329: Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

Suspended
1/2
7
US
CPO107, JMT601
Conjupro Biotherapeutics, Inc.
CD20 Positive Non Hodgkin Lymphoma
12/24
12/24

Download Options